PCSK9 Inhibitors – a solution for familial hypercholesterolaemia and ischaemic heart disease?
PCSK9 stands for Proprotein Convertase Subtilisin Kexin type 9 and it was first discovered in 2003[1] by Dr. Seidah et al. and it is a 692-amino acid glycoprotein.[2] PCSK9 is secreted by the liver into the circulation[3] and it controls the “number of low-density lipoprotein receptors (LDLR) on the cell surface”[4] and therefore ultimately the …